Tuberculosis (TB) remains one of the leading causes of death by a communicable agent,
infecting up to one-quarter of the world's population, predominantly in disadvantaged …

Featured Application Model-informed drug discovery and development (MID3) is proposed
to be applied throughout the preclinical to clinical phases to provide an informative …

Tuberculosis (TB) treatment is long and complex, typically involving a combination of drugs
taken for 6 months. Improved drug regimens to shorten and simplify treatment are urgently …

Aims Despite evidence of the efficacy of anti‐tubercular drug regimens in clinical practice,
the rationale underpinning the selection of doses and companion drugs for combination …

Here, we evaluate protocol requirements to mimic therapeutically relevant drug
concentrations at the site of infection (ie lung lesion) in an in-vitro hollow fibre model of …

Background and Purpose Translational efforts in the evaluation of novel anti‐tubercular
drugs demand better integration of pharmacokinetic–pharmacodynamic data arising from …

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium
tuberculosis. According to the WHO, the disease is one of the top 10 causes of death of …

Biomedical informatics has traditionally adopted a linear view of the informatics process
(collect, store and analyse) in translational medicine (TM) studies; focusing primarily on the …

Background Despite wide clinical acceptance, the use of weight-banded dosing regimens
for the treatment of TB in adults has been defined on an empirical basis. The potential …

The development of novel candidate molecules for tuberculosis remains challenging, as
drug distribution into the target tissue is not fully characterised in preclinical models of …